Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
April 25 2024 - 4:05PM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, today announced an ePoster flash session presentation at
the 34th European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona,
Spain.
The presentation highlights ALG-097558 Phase 1 data showing that
single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days)
doses of this potent, pan-coronavirus protease inhibitor were well
tolerated in healthy volunteers with a PK profile supporting twice
daily ritonavir-free dosing without a food effect.
“We are pleased to present these ALG-097558 data, which further
highlight the best-in-class potential of this pan-coronavirus
protease inhibitor and its substantial differentiation versus
current standard of care coronavirus antiviral drugs like
nirmatrelvir/ritonavir (PAXLOVIDTM),” said Lawrence Blatt, Ph.D.,
MBA, Chairman, President, and Chief Executive Officer at Aligos
Therapeutics. “These data further demonstrate that Aligos has
developed a robust clinical pipeline of three potentially
best-in-class drug candidates. We look forward to continuing to
advance ALG-097558 for current and potential future pandemics with
the financial support of various external funding sources,
including government agencies.”
Details of the presentation are as follows:
- ePoster Flash Session Presentation Title:
Safety and pharmacokinetics of single and multiple ascending doses
of ALG-097558, a pan-coronavirus protease inhibitor, in healthy
volunteers
- Presented by Denisa Wilkes, MD, MSc,
CPM, Medical Director, Hammersmith Medicines Research
- April 28, 2024 at 8:30am CEST
The presentation will be available on the Scientific
Presentations & Conferences section of the Aligos website
(www.aligos.com) after the live event.
About AligosAligos Therapeutics, Inc. is a
clinical stage biopharmaceutical company that was founded in 2018
with the mission to become a world leader in the treatment of liver
and viral diseases. Aligos’ strategy is to harness the deep
expertise and decades of drug development experience its team has
in liver and viral diseases to discover and develop potentially
best-in-class therapeutics for metabolic dysfunction-associated
steatohepatitis (MASH) and viruses with high unmet medical need
such as hepatitis B and coronaviruses.
PAXLOVID® is a registered trade mark of Pfizer, Inc.
Forward-Looking Statement This press release
contains forward-looking statements within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995. Any statements in
this press release that are not historical facts may be considered
“forward-looking statements,” including without limitation,
statements, with respect to ALG-097558, that the Phase 1 data
supports twice daily ritonavir-free dosing without food effect and
highlights best-in-class potential and substantial differentiation
versus standard of care coronavirus antiviral drugs; that such data
further demonstrate that Aligos has developed a robust clinical
pipeline of three potentially best-in-class drug candidates; and
that the company is looking forward to continuing to advance
ALG-097558 for current and potential future pandemics with the
financial support of various external funding sources, including
government agencies. Forward-looking statements are typically, but
not always, identified by the use of words such as “may,” “will,”
“would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,”
“expect,” and other similar terminology indicating future results.
Such forward looking statements are subject to substantial risks
and uncertainties that could cause our development programs, future
results, performance, or achievements to differ materially from
those anticipated in the forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
inherent in the drug development process, including Aligos’
clinical-stage of development, the process of designing and
conducting clinical trials, the regulatory approval processes, the
timing of regulatory filings, the challenges associated with
manufacturing drug products, Aligos’ ability to successfully
establish, protect and defend its intellectual property, other
matters that could affect the sufficiency of Aligos’ capital
resources to fund operations, reliance on third parties for
manufacturing and development efforts, and the impact of global
events and other macroeconomic conditions on the Aligos’ business.
For a further description of the risks and uncertainties that could
cause actual results to differ from those anticipated in these
forward-looking statements, as well as risks relating to the
business of Aligos in general, see Aligos’ Quarterly Report on Form
10-K filed with the Securities and Exchange Commission on March 12,
2024 and its future periodic reports to be filed or submitted with
the Securities and Exchange Commission. Except as required by law,
Aligos undertakes no obligation to update any forward-looking
statements to reflect new information, events or circumstances, or
to reflect the occurrence of unanticipated events.
Contacts
CompanyJordyn TaraziVice President, Investor
Relations & Corporate Communications(650)
910-0427jtarazi@Aligos.com
MediaMichael Fitzhugh LifeSci Communications
mfitzhugh@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Apr 2024 to May 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From May 2023 to May 2024